Related Experiment Video

Updated: Apr 14, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.3K

[Immediate and remote results of endovascular treatment of patients with postinfarction cardiosclerosis]

A V Patrikeev1, V Ia Rudman2, D A Maksimkin1

  • 1Rossiĭskiĭ universitet druzhby narodov, Moskva; Tsentral'naia klinicheskaia bol'nitsa #2 im. N.A. Semashko OAO "RZhD", Moskva.

Khirurgiia
|April 25, 2015
PubMed

Insights

Restoring coronary blood flow after myocardial infarction prevents heart remodeling and heart failure. Evaluating myocardial viability before revascularization improves outcomes and reduces unnecessary interventions.

Area of Science:

  • Cardiology
  • Cardiovascular Surgery
  • Interventional Cardiology

Context:

  • Postinfarction cardiosclerosis affects numerous patients, leading to heart remodeling and potential heart failure.
  • Current treatment strategies involve myocardial revascularization to restore coronary blood flow.
  • Differentiating between "total" and "selective" revascularization approaches is crucial for optimizing patient outcomes.

Purpose:

  • To compare the efficacy of "total" versus "selective" myocardial revascularization in patients with postinfarction cardiosclerosis.
  • To evaluate the impact of assessing myocardial viability on revascularization outcomes.
  • To determine the effect of revascularization on preventing adverse cardiac remodeling and heart failure.

Summary:

  • This study compared "total" (all significant lesions) and "selective" (viable myocardium only) revascularization in 131 patients with postinfarction cardiosclerosis.
  • Selective revascularization, guided by myocardial viability assessment, demonstrated increased efficiency, reduced stent usage, and fewer unnecessary interventions.
  • Restoration of coronary blood flow effectively prevents postinfarction heart remodeling and heart failure, positively impacting prognosis.

Impact:

  • Assessing myocardial viability enhances revascularization effectiveness, minimizes stent implantation, and decreases unwarranted coronary interventions.
  • Eliminating ischemia in hibernating myocardium segments leads to rapid restoration of left ventricular contractility.
  • The duration of myocardial hibernation prior to revascularization influences the timeline for contractility recovery.

More Related Videos

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.6K
Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

12.5K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
702
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
801
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
327
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
490
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
775
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
423